Monograph Details
|
|
Endocrine System
> Diabetes
|
|
LANTUS |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Insulin glargine (recombinant) 100 IU/mL; inj; contains m-cresol. |
| Indications |
|
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed. |
| Adults and Children |
|
Give once daily at same time each day; SC inj only. Onset 1.1 hrs, no pronounced peak, duration 24 hrs or longer. <6yrs: not recommended. ≥6yrs: individualize; monitor and adjust as needed. Switching from once-daily NPH or ultralente insulin: initial dose should be the same on a unit-for-unit basis. Switching from twice-daily NPH: reduce initial insulin glargine dose by 20% from previous total NPH dose. Insulin-naive, type 2 diabetics on oral antidiabetic: initially 10 IU; range 2–100 IU. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Do not mix or dilute with other insulins. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. |
| Adverse Reactions |
|
Pain, other inj site reactions, pruritus, rash, hypoglycemia, hypokalemia, lipodystrophy, edema. |
| How Supplied |
Vials (10mL)—1
Cartridges (3mL)—5 (for OptiClik)
Lantus SoloStar pen (prefilled, disposable inj device)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
